Reflecting the increasing importance of genetics in all areas of medicine, reproductive medicine of course included, this issue of the _VOICE _contains two major articles pertaining to genetics. In our lead article for the month, we are discussing the relatively new scientific field of “epigenetics,” which, in turn, has revolutionized genetics in general. After the good, we also have to talk a little bit about the not-so-good, and are addressing how the rapidly growing genetic lab testing industry is not always doing things in the best interest of the public and treating physicians. As always, not everybody will agree with our position on the subject, but we, of course, welcome critical comments.
In addition, we continue with our very popular series of Questions from the Public as we address this time the possible side effects of DHEA supplementation and what happens when only one ovary responds to stimulation for IVF. As always, when we address here androgen supplementation of any kind (including DHEA supplementation), please remember that CHR and CHR investigators are listed on quite a number of U.S. patents as inventors and receive royalties from companies that sell DHEA in order to improve female fertility. An additional DHEA patent, which addresses the positive effects of DHEA supplementation on female sexual wellbeing, is currently pending. This is a subject not discussed widely enough, and, therefore, also subject of a brief article in this issue of the VOICE. Considering the commercial connotations of those patents, please consider potential conflicts of interests when reading these articles.
In this issue of the VOICE, we cover:
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
DISCOVER YOUR TREATMENT OPTIONS
